Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis

Cancer patients produce autoantibodies to self‐proteins called tumor‐associated antigens (TAA). These autoantibodies represent potentially valuable tools for identifying novel biomarkers and therapeutic targets. This study was designed to identify TAA in prostate cancer (PCa).

[1]  James A Koziol,et al.  Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  E. Tan.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. , 2001, The Journal of clinical investigation.

[3]  J. Fitzpatrick,et al.  Heat shock proteins: their role in urological tumors. , 2003, The Journal of urology.

[4]  A. Rosen,et al.  Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease , 1999, Cell Death and Differentiation.

[5]  M. Spitz,et al.  Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case‐control analysis , 2003, Molecular carcinogenesis.

[6]  L. Chylack,et al.  Heparin's roles in stabilizing, potentiating, and transporting LEDGF into the nucleus. , 2000, Investigative ophthalmology & visual science.

[7]  G. Ronquist,et al.  Autoantibodies to Prostasomes as New Markers for Prostate Cancer , 2001, Upsala journal of medical sciences.

[8]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[9]  Guido Kroemer,et al.  Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.

[10]  Arturo Carta,et al.  Oxidative Stress and Age-Related Cataract , 2000, Ophthalmologica.

[11]  T. Daniels,et al.  Caspase cleavage of the nuclear autoantigen LEDGF/p75 abrogates its pro-survival function: implications for autoimmunity in atopic disorders , 2002, Cell Death and Differentiation.

[12]  L. Liotta,et al.  Identification of a novel transcript up-regulated in a clinically aggressive prostate carcinoma. , 1997, Urology.

[13]  E. Tan,et al.  Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes , 1998, Cell Death and Differentiation.

[14]  F. Shi,et al.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer , 2003, Clinical and experimental immunology.

[15]  D. P. Singh,et al.  LEDGF, a survival factor, activates stress-related genes , 2002, Progress in Retinal and Eye Research.

[16]  G. Wilding,et al.  Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. , 1997, Journal of the National Cancer Institute.

[17]  M. Hollstein,et al.  Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. , 1996, Cancer research.

[18]  D. S. Coffey,et al.  New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. , 1999, Urology.

[19]  J. Neoptolemos,et al.  Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.

[20]  E. Chan,et al.  Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. , 2001, Clinical immunology.

[21]  T. Zollner,et al.  Redox-modulated pathways in inflammatory skin diseases. , 2001, Free radical biology & medicine.

[22]  S. J. Monahan,et al.  Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. , 2002, Biochemical and biophysical research communications.

[23]  F. Chen,et al.  The Small Heat Shock Protein αB-Crystallin Negatively Regulates Cytochrome c- and Caspase-8-dependent Activation of Caspase-3 by Inhibiting Its Autoproteolytic Maturation* , 2001, The Journal of Biological Chemistry.

[24]  R. Roeder,et al.  Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation , 1998, The EMBO journal.

[25]  Gerd Ritter,et al.  Immunotherapeutic Targets Cancer : Identification of Potential Diagnostic and Cancer-related Serological Recognition of Human Colon Updated , 2002 .

[26]  R. Ablin.  Malignancy associated with antinuclear antibodies. , 1972, Lancet.

[27]  E. Rieber,et al.  Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. , 2000, Cancer research.

[28]  L. Chylack,et al.  Transcriptional Regulation of the Antioxidant Protein 2 Gene, a Thiol-specific Antioxidant, by Lens Epithelium-derived Growth Factor to Protect Cells from Oxidative Stress* , 2001, The Journal of Biological Chemistry.

[29]  L. Chylack,et al.  Review: Age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). , 2000, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[30]  T. Daniels,et al.  LEDGF/p75: a novel nuclear autoantigen at the crossroads of cell survival and apoptosis. , 2003, Autoimmunity reviews.

[31]  John Savill,et al.  Corpse clearance defines the meaning of cell death , 2000, Nature.

[32]  L. Chylack,et al.  Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. , 2000, Biochemical and biophysical research communications.

[33]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[34]  E. De Clercq,et al.  LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells* , 2003, Journal of Biological Chemistry.

[35]  C. Casiano,et al.  Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. , 2001, Arthritis and rheumatism.

[36]  Kim-Anh Do,et al.  Fingerprinting the circulating repertoire of antibodies from cancer patients , 2003, Nature Biotechnology.

[37]  M. Lucia,et al.  Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. , 2004, The Journal of urology.

[38]  E. Solary,et al.  Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. , 2003, Biochemical and biophysical research communications.

[39]  R. Ablin.  Serum Antibody in Patients with Prostatic Cancer1 , 1976 .

[40]  E. Chan,et al.  Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. , 2000, The Journal of allergy and clinical immunology.

[41]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  C. Akdis,et al.  Role of Apoptosis in Atopic Dermatitis , 2001, International Archives of Allergy and Immunology.

[43]  J. Fitzpatrick,et al.  Heat‐shock proteins inhibit induction of prostate cancer cell apoptosis , 2000 .

[44]  C. Akdis,et al.  T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. , 2002, The Journal of allergy and clinical immunology.

[45]  J. Epstein,et al.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. , 1999, The American journal of pathology.

[46]  E. Smeland,et al.  Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display , 2004, Cancer Immunology, Immunotherapy.

[47]  P. Anderson,et al.  Death, autoantigen modifications, and tolerance , 2000, Arthritis research.

[48]  R. Bowler,et al.  Oxidative stress in allergic respiratory diseases. , 2002, The Journal of allergy and clinical immunology.

[49]  R. Hiipakka,et al.  Anti-5α-Reductase Autoantibodies in the Serum of Patients with Prostatic Cancer , 1990 .

[50]  M. Montenarh,et al.  p53 autoantibodies in patients with urological tumours. , 1998, British journal of urology.